CRBP Corbus Pharmaceuticals Holdings
$8.12▼ -1.46%
Healthcare
Other
After hours
$10.44▲ +28.57%
Sep 11, 7:59 PM ET
Volume 1.47M
Avg Volume (10D) 621.3K
Key Metrics & Fundamentals
Market Cap
$157.05M
P/E Ratio
–
Div Yield
–%
52W Range
7.12 - 20.56
% vs 50 MA
-15.49%
% vs 200 MA
-10.88%
RSI-14
30.4
MACD Histogram
-0.3100
Beta (1Y vs SPY)
1.09
Free Cash Flow
-$29.63M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$36.14M
COGS
–
Operating Exp
$36.19M
Operating Income
-$36.19M
EBIT
-$36.19M
Pretax Income
-$35.04M
Net Income
-$35.04M
EPS (Diluted)
-1.81
Price & Volume History
Loading chart…
Recent News
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
GlobeNewswire · Sep 11, 2026 8:01 PM
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 17, 2026 2:00 PM
Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating
MT Newswires · Aug 13, 2026 9:22 AM
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating
MT Newswires · Aug 7, 2026 1:18 PM
Corbus Pharmaceuticals: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 12:12 PM
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
GlobeNewswire · Aug 6, 2026 12:00 PM
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
GlobeNewswire · Aug 4, 2026 12:30 PM
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
GlobeNewswire · Jul 28, 2026 12:00 PM
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
GlobeNewswire · Jul 6, 2026 12:00 PM
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating
MT Newswires · Jun 17, 2026 12:31 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CRBP's money flow as a full page
Social Sentiment
Avg +0.27 · 3 posts
DDNewsDiscussionCRBP: I think this is one of the most overlooked biotech catalysts of 2026
r/stocks · Jul 29, 2026
The author expresses a bullish outlook on CRBP's upcoming obesity readout and suggests the market is underestimating potential positive results.
positive
+0.70
CRBP Corbus Pharmaceuticals just announced FDA fast tract designation on new drug.
r/stocks · Dec 3, 2024
The announcement of FDA fast track is generally considered positive news for the company and its stock.
positive
+0.70
Should I be selling my CRBP stock? I'm getting mixed results.
r/stocks · Sep 21, 2024
The post expresses concern about negative side effects and a declining stock price, indicating a bearish sentiment.
negative
-0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.